Literature DB >> 16982557

IGRT of prostate cancer; is the margin reduction gained from daily IG time-dependent?

Marika Enmark1, Stine Korreman, Håkan Nyström.   

Abstract

The aim of this study was to assess the set-up uncertainties and the possible CTV-PTV margin reduction when adopting daily IGRT. Further, to identify any intrafraction time trends in the prostate movements to ensure the margin reduction gained from IGRT. Fifteen prostate cancer patients treated with IMRT using daily IG of three implanted fiducial markers were included. The interfraction uncertainties were assessed by statistically evaluating the daily prostate marker displacement. The intrafraction uncertainties were represented by the difference in prostate marker displacement before and after beam delivery. To evaluate any intrafraction time trends, the data points were divided into two groups with respect to time duration and statistically analysed. This study confirmed that daily IG considerably reduces the set-up uncertainties. Our results implied that if IGRT is performed on a daily basis, both systematic and random set-up errors will be reduced to a minimum, leading to a required set-up margin of only 1.5 mm. Results from measurements of intrafraction motions in time durations ranging from 2 to 27 min, indicated that a margin enlargement of 1 mm was required to account for the intrafraction uncertainties. The results did not suggest any significant time trends in the intrafraction uncertainties.

Entities:  

Mesh:

Year:  2006        PMID: 16982557     DOI: 10.1080/02841860600907337

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  8 in total

1.  Residual translational and rotational errors after kV X-ray image-guided correction of prostate location using implanted fiducials.

Authors:  Reinhold Graf; Dirk Boehmer; Volker Budach; Peter Wust
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

2.  Preliminary results of intensity-modulated radiation therapy with helical tomotherapy for prostate cancer.

Authors:  Natsuo Tomita; Norihito Soga; Yuji Ogura; Norio Hayashi; Hidetoshi Shimizu; Takashi Kubota; Junji Ito; Kimiko Hirata; Yukihiko Ohshima; Hiroyuki Tachibana; Takeshi Kodaira
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-01       Impact factor: 4.553

3.  Reducing ExacTrac intrafraction imaging uncertainty for prostate stereotactic body radiotherapy using a pre-treatment CBCT.

Authors:  Barry Jordan; Luis Muñoz; Christopher Colyer
Journal:  Phys Eng Sci Med       Date:  2022-04-19

4.  Emission guided radiation therapy for lung and prostate cancers: a feasibility study on a digital patient.

Authors:  Qiyong Fan; Akshay Nanduri; Samuel Mazin; Lei Zhu
Journal:  Med Phys       Date:  2012-11       Impact factor: 4.071

5.  Change in prostate volume during extreme hypo-fractionation analysed with MRI.

Authors:  Adalsteinn Gunnlaugsson; Elisabeth Kjellén; Oskar Hagberg; Camilla Thellenberg-Karlsson; Anders Widmark; Per Nilsson
Journal:  Radiat Oncol       Date:  2014-01-13       Impact factor: 3.481

6.  Reply to the comments on "Setup error analysis in helical tomotherapy based image-guided radiation therapy treatments" by Slav Yartsev.

Authors:  Bhagyalakshmi Akkavil Thondykandy; Jamema V Swamidas; Jay Prakash Agarwal; Tejpal Gupta; Sarbani G Laskar; Umesh Mahantshetty; Shrinivasan S Iyer; Indrani U Mukherjee; Shyam K Shrivastava; Deepak D Deshpande
Journal:  J Med Phys       Date:  2016 Jan-Mar

7.  Treatment plan comparison between Tri-Co-60 magnetic-resonance image-guided radiation therapy and volumetric modulated arc therapy for prostate cancer.

Authors:  Jong Min Park; So-Yeon Park; Chang Heon Choi; Minsoo Chun; Jin Ho Kim; Jung-In Kim
Journal:  Oncotarget       Date:  2017-08-08

8.  Dosimetric comparison of MR-linac-based IMRT and conventional VMAT treatment plans for prostate cancer.

Authors:  Vanessa Da Silva Mendes; Lukas Nierer; Minglun Li; Stefanie Corradini; Michael Reiner; Florian Kamp; Maximilian Niyazi; Christopher Kurz; Guillaume Landry; Claus Belka
Journal:  Radiat Oncol       Date:  2021-07-21       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.